详细内容请参见《华润三九医药股份有限公司 2026 年度日常关联交易预计金额的 公告》（2025-087）。 该议案将提交下一次股东会审议。 表决结果：5 票同意，0 票反对，0 票弃权，审议通过。 特此公告。 股票代码：000999 股票简称：华润三九 编号：2025—086 华润三九医药股份有限公司 2025 年第九次监事会会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"华润三九"）监事会 2025 年第 九次会议于2025年12月9日上午在华润三九医药工业园综合办公中心107会议室召开。 会议通知以书面方式于 2025 年 12 月 6 日发出。会议由监事会主席陶然先生主持，本次 会议应到监事 5 人，实到监事 5 人。本次会议的召开及程序符合《公司法》和《公司章 程》的规定，会议合法有效。会议以投票方式审议通过了以下议案，并形成决议： 一、关于 2026 年度日常关联交易预计金额的议案 华润三九医药股份有限公司监事会 二○二五年十二月九日 ...

股票代码：000999 股票简称：华润三九 编号：2025—085 华润三九医药股份有限公司 2025 年第十四次董事会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"或"华润三九"）董事会 2025 年 第十四次会议于 2025 年 12 月 9 日上午在华润三九医药工业园综合办公中心 107 会议室 召开。会议通知以书面方式于 2025 年 12 月 6 日发出。会议由公司董事长邱华伟先生主 持，本次会议应到董事 11 人，实到董事 11 人，公司监事会成员和部分高级管理人员列 席会议。本次会议的召开及程序符合《公司法》和《公司章程》的规定，会议合法有效。 会议以投票方式审议通过了以下议案，并形成决议： 一、 关于 2026 年度日常关联交易预计金额的议案 本议案提交董事会前已经公司独立董事专门会议全体成员同意并发表相关意见。 详细内容请参见《华润三九医药股份有限公司 2026 年度日常关联交易预计金额的 公告》（2025-087）。 关联董事白晓松先生、崔兴品先生、于舒天先生、梁柱强先生回避了表决。 ...

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market position [1][3]. Product Information - Product Name: Yiqi Qingfei Granules - Drug Classification Code: ZA09G - Drug Type: Traditional Chinese Medicine (TCM) - Registration Category: TCM Class 3.2 - Dosage Form: Granules - Agreement Validity: January 1, 2026, to December 31, 2027 - Indications: Used for symptoms related to Qi and Yin deficiency, spleen deficiency, and dampness, including fatigue, shortness of breath, dry cough, and gastrointestinal discomfort [1][2]. Impact on the Company - Yiqi Qingfei Granules received its drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and sales activities. The inclusion in the National Medical Insurance Directory is expected to have a positive impact on the company's product layout in the respiratory field, although it is not anticipated to significantly affect short-term operating performance [3].

Core Viewpoint - China Resources Sanjiu (华润三九) has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory, which is expected to enhance its product portfolio in the respiratory field, although it is not anticipated to have a significant short-term impact on the company's financial performance [1]. Group 1: Company Performance - As of December 8, 2025, China Resources Sanjiu's stock closed at 28.15 yuan, down 0.49% from the previous trading day, with a total market capitalization of 46.848 billion yuan [1]. - The stock opened at 28.3 yuan, reached a high of 28.39 yuan, and a low of 28.1 yuan, with a trading volume of 2.25 billion yuan and a turnover rate of 0.48% [1]. Group 2: Product Development - Yiqi Qingfei Granules, classified as a traditional Chinese medicine (Category 3.2), is indicated for short-term symptoms following epidemics related to Qi and Yin deficiency, spleen deficiency, and residual pathogenic factors [1]. - The product was approved for market launch in January 2025 and is currently undergoing post-market academic promotion and online sales [1]. - Inclusion in the National Medical Insurance Directory will take effect from January 1, 2026, with the agreement valid until December 31, 2027 [1].

Core Viewpoint - The company Huazhu Sanjiu announced that its drug Yiqi Qingfei Granules has been included in the National Medical Insurance Directory (2025 version) for the first time [1][2] Group 1: Product Approval and Market Entry - Yiqi Qingfei Granules received the Drug Registration Certificate from the National Medical Products Administration, officially approved for market launch in January 2025 [1][2] - The company is currently conducting academic promotion and online sales activities for Yiqi Qingfei Granules in an orderly manner [1][2]

公告显示，益气清肺颗粒于2025年1月获得国家药品监督管理局颁发的《药品注册证书》，正式获批上 市。适应症为益气养阴，健脾和中，清热祛湿，适用于疫病后短期症状，气阴两虚，脾虚失运，余邪未 尽证，症见倦怠乏力、动后气短、干咳少痰、咽喉不利、胃脘痞闷、纳呆便溏，舌淡或红、少津，脉细 数。 北京商报讯（记者 王寅浩 宋雨盈）12月8日，华润三九发布公告称，公司药品益气清肺颗粒通过谈判首 次纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，协议有效期为2026年1月1日 至2027年12月31日。 ...

Core Viewpoint - China Resources Sanjiu Pharmaceutical Co., Ltd. has successfully included its product Yiqi Qingfei Granules in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025 version) through negotiations, which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market leadership position [1] Group 1 - Yiqi Qingfei Granules received the drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and online sales [1] - The 2025 version of the National Medical Insurance Catalog will officially take effect on January 1, 2026, marking the first inclusion of Yiqi Qingfei Granules in this catalog [1] - The short-term impact on the company's operating performance is not expected to be significant, but the inclusion is seen as a positive step for the company's strategic positioning in the respiratory product sector [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 through negotiations [1] Group 1 - The inclusion of Yiqi Qingfei Granules marks a significant milestone for the company, enhancing its market access and potential revenue streams [1] - This decision is part of a broader initiative by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security to update the drug catalog [1]

华润三九（000999）(000999.SZ)公告，据国家医保局、人力资源社会保障部关于印发《国家基本医疗 保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》的通知，公司药品益气清肺 颗粒通过谈判首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》。 ...

Core Viewpoint - China Resources Sanjiu Pharmaceutical Co., Ltd. has successfully included its product Yiqi Qingfei Granules in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025 version) through negotiations, which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market leadership position [1] Group 1 - Yiqi Qingfei Granules received the drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and online sales [1] - The National Medical Insurance Catalog (2025 version) will officially take effect on January 1, 2026, marking the first inclusion of this drug in the catalog [1] - The short-term impact on the company's operating performance is not expected to be significant, but the inclusion is seen as a positive step for the company's strategic positioning in the respiratory sector [1]